Clinical role of Tc-99m-MIBI scintigraphy in non-Hodgkin's lymphoma

Citation
M. Ohta et al., Clinical role of Tc-99m-MIBI scintigraphy in non-Hodgkin's lymphoma, ONCOL REP, 8(4), 2001, pp. 841-845
Citations number
15
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Oncology
Journal title
ONCOLOGY REPORTS
ISSN journal
1021-335X → ACNP
Volume
8
Issue
4
Year of publication
2001
Pages
841 - 845
Database
ISI
SICI code
1021-335X(200107/08)8:4<841:CROTSI>2.0.ZU;2-J
Abstract
This study was designed to investigate the relationship between Tc-98m-hexa kis-2-methoxyisobutyl-isonitrile (MIBI) scintigraphy and outcome of treatme nt in patients with non-Hodgkin's lymphoma. (NHL). Forty-five patients with NHL were studied with Tc-99m-MIBI before any treatment. Images of the lesi ons were obtained at 20 min and 2 h after radionuclide administration. Visu al semiquantitative interpretation was performed for Tc-99m-MIBI (grade 0-4 ) scintigraphy. Patients underwent 3-5 cycles of CHOP chemotherapy with/wit hout involved field radiotherapy for large tumors. Their responses to treat ment were evaluated at the end of chemotherapy and during the follow-up per iod. Forty of 45 patients (89%) showed abnormal uptake of Tc-99m-MIBI. Ther e was no correlation between intensity of MIBI accumulation and response to chemotherapy. However, patients with negative or decreased MIBI activity 2 h after radionuclide administration showed worse response to chemotherapy compared to those with continued MIBI activity. MIBI activity could not pre dict the development of relapse in the follow-up study. In this study, the number of patients was small and we could not reach definite conclusions. H owever, we think that MIBI scintigraphy is not valuable For predicting the chemotherapy outcome in patients with NHL.